Wisdom Pharmaceuticals: Subsidiary collaborates in the development of ADC and nucleotide monomer automated, intelligent, integrated desktop synthesis system.

Wisdom Pharmaceuticals announced on November 10th that its wholly-owned subsidiary, Shanghai Wisdom Pharmaceutical Research Group Co., Ltd., has successfully collaborated with East China Normal University to independently develop an automated, intelligent, and integrated desktop synthesis system for antibody-drug conjugates and nucleoside monomers. This system can seamlessly connect laboratory research to industrial production and reconstruct paradigms. The application of ADC and nucleoside monomer automated, intelligent, and integrated desktop synthesis system can significantly shorten the research and development cycle, improve research and development efficiency, and help the company provide higher quality services to customers.